Menu Back to Advancing-Diversity-Equity-and-Inclusion-Across-Life-Sciences-R-D-Meeting

Overview

Conference: October 6-7

DIA’s Advancing Diversity, Equity, and Inclusion Across Life Sciences R&D Meeting will lead the way in sharing knowledge and fostering coalitions to build greater diversity, equity, and inclusion efforts in the life sciences R&D field. Moving beyond describing the problems that exist in this space, this meeting will emphasize approaches and solutions in which our field has been investing over the years.

In 2021, our first meeting explored the challenges and best practices that exist in all phases of the lifecycle. This year, our newly revamped meeting will look beyond identifying the problem and provide actionable solutions and meaningful change that one can take back to their organization to implement and encourage change management. In 2020, the FDA released their final guidance titled, “Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs”, and in 2022, released their draft guidance titled, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Subgroups in Clinical Trials”. With the final and draft guidance documents that have been released from the FDA on this topic and the reinforcement of the importance on the inclusion of study populations in clinical research mirroring and reflecting the characteristics of the population ultimately affected by a particular illness or condition, this meeting is helpful to those who are new to this space or have worked on these efforts for years.

The meeting will include interactive and compelling discussions and exercises that will lead to a better understanding of how we can improve as an industry to encourage accountability and sustainability of efforts. An important purpose of the meeting is to advance dialogue among thought leaders from industry, clinical research sites, patient engagement, academia, the FDA, and public policy to spur additional ideas to move the field forward.

This program has been developed in collaboration with the Diversity in Life Sciences Community.


While we develop our 2022 Agenda, please take a look at the 2021 final agenda


Who should attend?

Professionals involved in:
  • Clinical Research
  • Clinical Operations
  • Data transparency/data sharing
  • Diversity, Equity and Inclusion
  • Health Outcomes
  • Medical Affairs and Communication
  • Patient Advocacy
  • Patient Engagement/Patient Support
  • Professional Education, Training and Development
  • Public Policy
  • Research and Development
  • Regulatory Affairs
  • Strategic Planning

Learning objectives

At the conclusion of this activity, participants should be able to:
  • Describe the US FDA’s priorities, guidances that relate to diversity, equity, and inclusion, and efforts to advance the inclusion of minorities and women in clinical trials
  • Describe the challenges of protocol development and design, its influence on clinical trial recruitment and enrollment, and the role of the institutional review board (IRB) and independent ethics committees (IEC)
  • Evaluate the challenges that impact diversity recruitment, enrollment, and retention in clinical trials
  • Identify industry efforts, strategies, lessons learned, and best practices that support clinical trial diversity in drug development
  • Explain clinical research site activities that advance clinical trial diversity through community engagement
  • Describe the importance of data, how it is interpreted and collected, and the utilization of real-world data and real-world evidence
  • Recognize the importance of a change agent and how to effectively implement culture change and change management into an organization
  • Describe the current talent pipeline, how to increase the diversity of talent, and the barriers and factors that prevent opportunities for underrepresented communities
  • Recognize how to engage and be proactive to the needs of diverse communities to foster trust and relationship building

Program Committee

  • Richardae  Araojo, PharmD, MS
    Richardae Araojo, PharmD, MS Associate Commissioner for Minority Health, Director, Office of Minority Health
    FDA, United States
  • Dyan  Bryson, MBA
    Dyan Bryson, MBA Patient Engagement Strategist
    Inspired Health Strategies, LLC, United States
  • Diana  Foster, BSN, PhD, MSN
    Diana Foster, BSN, PhD, MSN CEo
    Total Diversity Clinical Trial Management, United States
  • Karen  Correa, PhD
    Karen Correa, PhD Vice President, Head Global Clinical Operations
    Takeda, United States
  • Tamei  Elliott, MS
    Tamei Elliott, MS Senior Manager, Scientific Programs
    DIA, United States
  • Kevin  Freiert, MBA
    Kevin Freiert, MBA Owner/Principal
    Salem Oaks® Consulting, United States
  • Barbara  Goodman, MBA
    Barbara Goodman, MBA President and Chief Executive Officer
    Cures Within Reach, United States
  • Christine  Lee, PhD
    Christine Lee, PhD Strategic and Scientific Engagement Lead, OMH, OC
    FDA, United States
  • Alissa  Goodale, DrMed
    Alissa Goodale, DrMed Regulatory Executive Director
    Genentech, A Member of the Roche Group, United States
  • Amy  Sitnick, MA
    Amy Sitnick, MA Vice President, Marketing
    Greenphire, United States
  • Jacqueline  Woodruff
    Jacqueline Woodruff Clinical Researcher / Anthropologist
    Researcher, United States
  • Stephanie  Young Moss, PharmD, MS
    Stephanie Young Moss, PharmD, MS Pharmacist, Owner
    Integrative Pharmacy Outcomes and Consulting, United States
  • Session Chair Totally Invited
    Session Chair Totally Invited
    DIA, United States
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download